...
首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >YKL-40 is a novel biomarker for predicting hypertension incidence among prehypertensive subjects: A population-based nested case-control study in China
【24h】

YKL-40 is a novel biomarker for predicting hypertension incidence among prehypertensive subjects: A population-based nested case-control study in China

机译:YKL-40是一种新型生物标志物,用于预测毛细血压对象中的高血压发病率:中国的人口嵌套案例控制研究

获取原文
获取原文并翻译 | 示例

摘要

Abstract Background and aims The previous study suggested that Human cartilage glycoprotein-39 (YKL-40) was positively associated with hypertension incidence in certain high-risk groups of hypertension . We aimed to investigate that whether YKL-40 is an effective biomarker for predicting hypertension incidence among prehypertensive subjects. Methods In a 1:1 matched case-control study of 700 pairs with available YKL-40 levels nested in a prospective cohort of initially healthy Chinese subjects, 294 pairs additionally have matched baseline BP status (prehypertensive or normotensive). Multivariable conditional logistic regression analyses were used to calculate the odds ratios (95% confidential intervals) of hypertension associated with higher levels of YKL-40 in both prehypertensive and normotensive subgroups, respectively. Results In the prehypertensive subgroup, the subjects in the highest quartile of plasma YKL-40 levels had a significantly higher risk of hypertension incidence, compared with those in the lowest quartile. The odds ratio (95% confidential intervals) is 2.01 (1.05–3.85). A positive association between YKL-40 levels and hypertension incidence was found ( P for trend 0.05). However, this significant association was not observed in the normotensive subgroup. Conclusions Higher YKL-40 levels at baseline were positively associated with hypertension incidence among prehypertensive subjects. YKL-40 may represent a novel biomarker for predicting hypertension risk in prehypertension population. Highlights ? YKL-40 was positively associated with hypertension incidence among prehypertensive subjects. ? YKL-40 is a novel biomarker for predicting hypertension in prehypertension population. ? Lowering YKL-40 may be beneficial to slow down the development from prehypertension to hypertension. ]]>
机译:摘要背景和旨在先前的研究表明,人类软骨糖蛋白-39(YK1-40)与高血压群体的高血压发病率正相关。我们旨在调查YKL-40是否是用于预测预流血受试者的高血压发病率的有效生物标志物。方法1:1匹配案例对照研究700对,可用的YKL-40含量嵌套在最初健康的中国受试者,294对的前瞻性队列中,另外具有匹配的基线BP状态(预发性或正规)。多变量条件逻辑回归分析分别用于计算高血压和正常性亚组中具有较高水平YKL-40的高血压的差距(95%机密间隔)。结果在血浆血浆血浆YKL-40水平最高四分位数中的受试者具有明显较高的高血压发病率风险,与最低四分位数相比。赔率比(95%机密间隔)为2.01(1.05-3.85)。发现了YKL-40水平和高血压发病率之间的阳性关联(p用于趋势& 0.05)。然而,在正常的亚组中未观察到这种显着的关联。结论基线的较高的YKL-40水平与预流血受试者之间的高血压发病率呈正相关。 YKL-40可以代表一种新型生物标志物,用于预测粉末群体中的高血压风险。强调 ? YKL-40与预流血受试者之间的高血压发病率呈正相关。还YKL-40是一种新型生物标志物,用于预测毛细血管群中的高血压。还降低YKL-40可能有利于减缓从血浆到高血压的发展。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号